2012 г. – The Japanese producer of Teysuno Taiho Pharmaceutical and Nordic Group concluded an agreement for the commercialisation of the drug for the territory of EU as well as other countries.
Teysuno – An original, innovative, oral antitumour agent for the treatment of advanced stomach cancer (difficult and unsuccessful to cure up to now), given in combination with cisplatin.
Teysuno – 4th generation of oral fluoropyrimidin.
Teysuno – due to its innovative formula, a combination of three active substances– drug for stomach cancer with high efficiency and significantly reduced adverse effects (haematological and non-haematological )
Recommended dosage: 2 x 25 mg/m2 /daily x 21 days, followed by 7 days of rest (one therapeutic course), repeated every 4 weeks in combination with cisplatin 75 mg/m2 , applied on Day 1 of the course (A total of 6-8 courses of treatment)